Clariant (CLN) Aktienübersicht
Die Clariant AG entwickelt, produziert, vertreibt und verkauft Spezialchemikalien in der Schweiz, in Europa, im Nahen Osten, in Afrika, in den Vereinigten Staaten und in der Region Asien-Pazifik. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 4/6 |
CLN Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Clariant AG Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | CHF 7.83 |
| 52-Wochen-Hoch | CHF 9.06 |
| 52-Wochen-Tief | CHF 6.55 |
| Beta | 0.45 |
| 1 Monat Veränderung | 3.10% |
| 3 Monate Veränderung | -6.46% |
| 1 Jahr Veränderung | -8.37% |
| 3 Jahre Veränderung | -42.67% |
| 5 Jahre Veränderung | -58.60% |
| Veränderung seit IPO | -59.66% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jun 23
CLN: Pricing Power And Specialty Focus Will Drive Re Rating Potential
Clariant's analyst price target has been revised lower by CHF 1.40 to reflect a recalibrated fair value, with analysts citing recent cuts to CHF 7.50 from Deutsche Bank and Citi, as well as more balanced views from Goldman Sachs at CHF 8.50 and JPMorgan at CHF 9.30, as they reassess the stock's quality profile, pricing power and valuation. Analyst Commentary Recent research on Clariant points to a mixed but increasingly constructive tone, with several bullish analysts highlighting improving quality perceptions and a more supportive view on valuation.
Narrative-Update • Jun 07
CLN: Weaker Revenue Outlook And Conflict Exposure Will Restrain Future Upside
Analysts have modestly raised their fair value estimate for Clariant to CHF 6.00. Recent Street research, including a reduced price target of CHF 7.50 at Citi and an upgrade to Overweight with a CHF 9.30 target at JPMorgan, highlights differing views that center on discounted valuation and expectations for a higher-quality specialty chemicals profile.
Narrative-Update • May 24
CLN: Overweight Upgrade And Specialty Focus Will Shape Measured Forward Expectations
Analysts have trimmed their fair value estimate for Clariant to about CHF 8.58 from CHF 8.84, while still pointing to a CHF 9.30 price target. This target is supported by views that the stock’s current discounted valuation offers exposure to a higher quality specialty chemicals profile.Recent updates
Narrative-Update • Jun 23
CLN: Pricing Power And Specialty Focus Will Drive Re Rating Potential
Clariant's analyst price target has been revised lower by CHF 1.40 to reflect a recalibrated fair value, with analysts citing recent cuts to CHF 7.50 from Deutsche Bank and Citi, as well as more balanced views from Goldman Sachs at CHF 8.50 and JPMorgan at CHF 9.30, as they reassess the stock's quality profile, pricing power and valuation. Analyst Commentary Recent research on Clariant points to a mixed but increasingly constructive tone, with several bullish analysts highlighting improving quality perceptions and a more supportive view on valuation.Narrative-Update • Jun 07
CLN: Weaker Revenue Outlook And Conflict Exposure Will Restrain Future Upside
Analysts have modestly raised their fair value estimate for Clariant to CHF 6.00. Recent Street research, including a reduced price target of CHF 7.50 at Citi and an upgrade to Overweight with a CHF 9.30 target at JPMorgan, highlights differing views that center on discounted valuation and expectations for a higher-quality specialty chemicals profile.Narrative-Update • May 24
CLN: Overweight Upgrade And Specialty Focus Will Shape Measured Forward Expectations
Analysts have trimmed their fair value estimate for Clariant to about CHF 8.58 from CHF 8.84, while still pointing to a CHF 9.30 price target. This target is supported by views that the stock’s current discounted valuation offers exposure to a higher quality specialty chemicals profile.Narrative-Update • May 02
CLN: Trimmed Assumptions And Downgrades Will Shape Measured Forward Expectations
Analysts have trimmed their price target on Clariant by CHF 0.09 to reflect updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, in line with recent research that includes a downgrade from some firms. Analyst Commentary Bullish Takeaways Bullish analysts see the revised fair value and discount rate assumptions as more realistic.Narrative-Update • Apr 17
CLN: Earnings Quality And Steadier Cash Generation Will Support Bullish Re Rating
Analysts have trimmed their price target on Clariant to CHF 12.37 from CHF 12.77, citing updated assumptions on discount rates, revenue growth, profit margins and future P/E following recent research, including a downgrade from Goldman Sachs. Analyst Commentary While the latest research includes a downgrade from Goldman Sachs, some views across the Street remain constructive, focusing on how Clariant could still convert its fundamentals into long term value creation.Narrative-Update • Apr 03
CLN: Recent Downgrade And Trimmed Assumptions Will Shape Potential Upside
Analysts have trimmed their CHF price targets for Clariant by a small amount, reflecting more cautious assumptions on revenue growth and profit margins. They are still applying a slightly higher future P/E multiple in their updated models.Narrative-Update • Mar 20
CLN: Lower CHF 7.80 Outlook Will Restrain Upside As Legal Claims Persist
Analysts have trimmed their average price target on Clariant to CHF 7.80 from CHF 8.00, reflecting slightly softer expectations that align with recent downgrades and more cautious assumptions on growth and returns. Analyst Commentary Recent research points to a more cautious stance on Clariant, with the latest moves reflecting concerns around execution, growth visibility and how the current share price lines up with those risks.Narrative-Update • Mar 05
CLN: Legal Claims And Recent Downgrade Will Frame Potential Upside Ahead
Analysts have trimmed their price expectations for Clariant, with the average target moving modestly lower to around CHF 7.80. This reflects updated assumptions on fair value, discount rates and future P/E in light of recent research calls.Narrative-Update • Feb 19
CLN: Legal Claims And Rating Downgrade Will Shape Measured Future Upside Potential
The updated analyst price target for Clariant now stands at CHF 8.80, a small change from the prior CHF 8.74, as analysts factor in recent target cuts around CHF 7.80 and adjust their assumptions on discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts see the updated CHF 8.80 target as reflecting a more refined view of discount rates and earnings power, rather than a fundamental shift in the story.Narrative-Update • Feb 05
CLN: Lower CHF 7.80 Outlook Will Cap Upside As Legal Claims Linger
Analysts have reduced their price target on Clariant to CHF 7.80 from CHF 8.00 to reflect updated views on the company’s discount rate, revenue growth assumptions, profit margins and future P/E. Analyst Commentary Bearish analysts are signaling a more cautious stance on Clariant by aligning their valuation work with a CHF 7.80 price level.Narrative-Update • Jan 22
CLN: Revised Expectations And Legal Claims Will Shape Future Upside Potential
Analysts have reduced their price target for Clariant to CHF 7.80 from CHF 8.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent research points to a more cautious stance on Clariant, with the price target trimmed to CHF 7.80 from CHF 8 and the rating held steady at Hold.Narrative-Update • Jan 07
CLN: Legal Claims And Steady Earnings Outlook Will Support Bullish Re Rating
Analysts have trimmed their price target on Clariant to CHF 7.80, reflecting updated assumptions for fair value, revenue growth, margins and future P/E multiples following recent research. Analyst Commentary Recent research points to a more measured stance on Clariant, with the revised CHF 7.80 target reflecting updated views on valuation, earnings power and the multiples investors might be willing to pay for the shares.Narrative-Update • Dec 21
CLN: Reduced Price Outlook Will Limit Upside Amid Rising Legal Risks
Analysts have reduced their price target on Clariant by CHF 1.50 to CHF 8.10, reflecting more cautious assumptions on revenue growth and valuation multiples, even though margin expectations have improved slightly. Analyst Commentary Bearish analysts have framed the lower price target as a reflection of rising skepticism around Clariant's ability to deliver on its medium term growth ambitions, despite recent progress on margins.Narrative-Update • Dec 07
CLN: Margin Recovery And Legal Overhang Will Shape Future Share Resilience
Analysts have trimmed their price target on Clariant by CHF 1.50 to reflect a slightly lower assumed future price to earnings multiple and discount rate, even as forecasts for profit margins have improved. Analyst Commentary Analysts remain balanced in their view on Clariant, with modest adjustments to valuation assumptions reflecting both improving profitability and lingering execution risks.Narrative-Update • Nov 23
CLN: Market Recovery And Margin Discipline Will Drive Future Share Resilience
Clariant's analyst price target has been revised downward from CHF 9.78 to CHF 9.51. Analysts cite tempered expectations for near-term performance amid evolving market conditions.Narrative-Update • Nov 07
CLN: Margin Improvements And Efficiency Efforts Will Offset Market Headwinds
Analysts have reduced their price target for Clariant from CHF 9.60 to CHF 8.10. This adjustment reflects lowered growth expectations and a more cautious outlook on the company's future performance.Analyseartikel • Nov 04
Cautious Investors Not Rewarding Clariant AG's (VTX:CLN) Performance Completely
There wouldn't be many who think Clariant AG's ( VTX:CLN ) price-to-earnings (or "P/E") ratio of 20.4x is worth a...Narrative-Update • Oct 24
Earnings Recovery Will Depend On Stabilization And Cost Improvements Amid Headwinds
Narrative Update: Clariant Analyst Price Target Adjustment Clariant’s analyst price target has been reduced significantly, dropping from CHF 9.60 to CHF 8.10. Analysts cite softer revenue growth and profit margin expectations in their revised outlook.Narrative-Update • Oct 10
China Expansion And Sustainable Solutions Will Boost Long-Term Appeal
Narrative Update on Clariant Clariant's analyst price target has been revised downward from CHF 10.95 to CHF 10.58. Analysts cite a combination of cautious revenue growth assumptions and a recent reduction in price targets by major banks.Narrative-Update • Sep 26
China Expansion And Sustainable Solutions Will Boost Long-Term Appeal
The minor decrease in Clariant's price target reflects a combination of lower revenue growth expectations and a modestly higher discount rate, resulting in a slight fair value reduction to CHF10.95. What's in the News Clariant AG dropped from the FTSE All-World Index (USD).Analyseartikel • Sep 17
Is Clariant AG (VTX:CLN) Trading At A 32% Discount?
Key Insights Clariant's estimated fair value is CHF11.89 based on 2 Stage Free Cash Flow to Equity Current share price...Analyseartikel • Aug 26
We Think Clariant (VTX:CLN) Is Taking Some Risk With Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Aug 08
Clariant's (VTX:CLN) Anemic Earnings Might Be Worse Than You Think
SWX:CLN 1 Year Share Price vs Fair Value Explore Clariant's Fair Values from the Community and select yours Clariant...Analyseartikel • May 30
Clariant (VTX:CLN) Has Affirmed Its Dividend Of CHF0.42
Clariant AG ( VTX:CLN ) has announced that it will pay a dividend of CHF0.42 per share on the 4th of June. Based on...Analyseartikel • May 05
These 4 Measures Indicate That Clariant (VTX:CLN) Is Using Debt Extensively
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Apr 13
Are Investors Undervaluing Clariant AG (VTX:CLN) By 39%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Clariant fair value estimate is CHF13.37 Current share price...Analyseartikel • Mar 26
Clariant AG's (VTX:CLN) CEO Might Not Expect Shareholders To Be So Generous This Year
Key Insights Clariant's Annual General Meeting to take place on 1st of April Salary of CHF1.20m is part of CEO Conrad...Analyseartikel • Mar 05
Clariant AG Just Missed EPS By 6.0%: Here's What Analysts Think Will Happen Next
It's been a sad week for Clariant AG ( VTX:CLN ), who've watched their investment drop 10% to CHF9.76 in the week since...Analyseartikel • Mar 02
Take Care Before Diving Into The Deep End On Clariant AG (VTX:CLN)
When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") above 21x, you may consider...
Neues Narrative • Dec 18
Restructuring, Lucas Meyer Cosmetics, And Sunliquid Set To Boost Margins And Drive Earnings
Identifying restructuring opportunities and targeting significant savings could improve Clariant's net margins and earnings efficiency in the coming years.Analyseartikel • Nov 27
Estimating The Intrinsic Value Of Clariant AG (VTX:CLN)
Key Insights The projected fair value for Clariant is CHF10.85 based on 2 Stage Free Cash Flow to Equity Clariant's...Analyseartikel • Nov 09
It's A Story Of Risk Vs Reward With Clariant AG (VTX:CLN)
Clariant AG's ( VTX:CLN ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy right now...Analyseartikel • Aug 07
Clariant's (VTX:CLN) Solid Earnings Have Been Accounted For Conservatively
The stock was sluggish on the back of Clariant AG's ( VTX:CLN ) recent earnings report. Our analysis suggests that...Analyseartikel • Jul 17
Why Investors Shouldn't Be Surprised By Clariant AG's (VTX:CLN) Low P/S
Clariant AG's ( VTX:CLN ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong buy right now...Analyseartikel • Apr 23
What Is Clariant AG's (VTX:CLN) Share Price Doing?
Clariant AG ( VTX:CLN ), might not be a large cap stock, but it received a lot of attention from a substantial price...Analyseartikel • Apr 03
Increases to Clariant AG's (VTX:CLN) CEO Compensation Might Cool off for now
Key Insights Clariant to hold its Annual General Meeting on 9th of April Total pay for CEO Conrad Keijzer includes...Analyseartikel • Nov 22
An Intrinsic Calculation For Clariant AG (VTX:CLN) Suggests It's 50% Undervalued
Key Insights The projected fair value for Clariant is CHF25.95 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Oct 31
Clariant (VTX:CLN) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aktionärsrenditen
| CLN | CH Chemicals | CH Markt | |
|---|---|---|---|
| 7D | 8.1% | -2.0% | -0.6% |
| 1Y | -8.4% | -9.2% | 16.4% |
Rendite im Vergleich zur Industrie: CLN wie die Branche Swiss Chemicals , die im vergangenen Jahr eine Rendite von -9.2 erzielte.
Rendite vs. Markt: CLN hinter dem Markt Swiss zurück, der im vergangenen Jahr eine Rendite von 16.4 erzielte.
Preisvolatilität
| CLN volatility | |
|---|---|
| CLN Average Weekly Movement | 4.3% |
| Chemicals Industry Average Movement | 4.3% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 2.1% |
Stabiler Aktienkurs: CLN hatte in den letzten 3 Monaten im Vergleich zum Swiss -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: CLNDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1886 | 9,998 | Conrad Keijzer | www.clariant.com |
Die Clariant AG entwickelt, produziert, vertreibt und verkauft Spezialchemikalien in der Schweiz, in Europa, im Nahen Osten, in Afrika, in den USA und in der Region Asien-Pazifik. Das Unternehmen ist in den Segmenten Care Chemicals, Catalysts und Adsorbents & Additives tätig. Das Segment Care Chemicals bietet Lösungen in den Bereichen Körperpflege, Pflanzenschutz, industrielle Anwendungen, Basischemikalien, Öldienstleistungen und Bergbau für verschiedene Anwendungen in den Bereichen Haushalts- und Körperpflege, Beschichtungen, Klebstoffe, Landwirtschaft und Lebensmittel.
Clariant AG's Grundlagenzusammenfassung
| CLN grundlegende Statistiken | |
|---|---|
| Marktanteil | CHF 2.60b |
| Gewinn(TTM) | -CHF 75.00m |
| Umsatz(TTM) | CHF 3.92b |
0.7x
Kurs-Umsatz-Verhältnis-34.3x
Kurs-Gewinn-Verhältnis Ist CLN zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CLN Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | CHF 3.92b |
| Kosten der Einnahmen | CHF 2.69b |
| Bruttogewinn | CHF 1.22b |
| Sonstige Ausgaben | CHF 1.30b |
| Gewinn | -CHF 75.00m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
Jul 31, 2026
| Gewinn per Aktie (EPS) | -0.23 |
| Bruttomarge | 31.19% |
| Nettogewinnspanne | -1.92% |
| Schulden/Eigenkapital-Verhältnis | 85.2% |
Wie hat sich CLN auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
5.4%
Aktuelle Dividendenrendite-184%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/15 17:33 |
| Aktienkurs zum Tagesende | 2026/07/15 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Clariant AG wird von 33 Analysten beobachtet. 15 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Volker Bosse | Baader Helvea Equity Research |
| Konstantin Wiechert | Baader Helvea Equity Research |
| Katie Richards | Barclays |